Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT
Background

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions
Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
Associated Therapies
Palliative Treatment

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China

First Posted Date
2018-07-26
Last Posted Date
2018-07-26
Lead Sponsor
Beijing Children's Hospital
Target Recruit Count
55
Registration Number
NCT03598725
Locations
🇨🇳

Beijing Children's Hospital, Beijing, Beijing, China

Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica

First Posted Date
2018-07-26
Last Posted Date
2022-06-10
Lead Sponsor
Sanofi
Target Recruit Count
118
Registration Number
NCT03600818
Locations
🇺🇸

Investigational Site Number 8400009, Stamford, Connecticut, United States

🇦🇷

Investigational Site Number 0320001, Buenos Aires, Argentina

🇷🇺

Investigational Site Number 6430001, Moscow, Russian Federation

and more 81 locations

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

First Posted Date
2018-07-23
Last Posted Date
2024-12-27
Lead Sponsor
Marlise Luskin, MD
Target Recruit Count
40
Registration Number
NCT03595917
Locations
🇺🇸

University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

🇺🇸

Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

First Posted Date
2018-07-17
Last Posted Date
2024-10-31
Lead Sponsor
Takeda
Target Recruit Count
245
Registration Number
NCT03589326
Locations
🇺🇸

Augusta University Georgia Cancer Center, Augusta, Georgia, United States

🇨🇦

Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada

🇧🇬

University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria

and more 89 locations

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

First Posted Date
2018-07-12
Last Posted Date
2024-01-24
Lead Sponsor
Incyte Corporation
Target Recruit Count
155
Registration Number
NCT03584516
Locations
🇺🇸

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

🇺🇸

Loyola University Medical Center, Maywood, Illinois, United States

🇺🇸

Jefferson University Hospitals, Philadelphia, Pennsylvania, United States

and more 130 locations

Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2018-06-21
Last Posted Date
2022-09-26
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
32
Registration Number
NCT03565835
Locations
🇺🇸

Montefiore Medical Center, Bronx, New York, United States

Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)

First Posted Date
2018-06-08
Last Posted Date
2019-04-03
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Target Recruit Count
108
Registration Number
NCT03549663
Locations
🇨🇳

Shanghai Xinhua Hospital affliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, Shanghai, China

RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor

First Posted Date
2018-05-24
Last Posted Date
2022-08-03
Lead Sponsor
Andres J. M. Ferreri
Target Recruit Count
28
Registration Number
NCT03536039
Locations
🇮🇹

Ospedale San Raffaele, Milan, Italy

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

First Posted Date
2018-04-27
Last Posted Date
2024-11-28
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
17
Registration Number
NCT03511196
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath